Results of Lucentis use as a routine practice in wet age-related macular degeneration patients

Cover Page

Abstract


Ranibizumab treatment leads to rapid visual acuity improvement, which may be observed in as little as a week after the first injection, and may lead to quality of life improvement as estimated by VFQ-25 questionnaire. The retinal thickness progressively decreased in the course of treatment, what along with the lesion size reduction results in visual function improvement. The quality of life assessment using the VFQ-25 questionnaire revealed an improvement in all subscale positions during first months of monitoring, when visual acuity increase helps the patient perform routine daily activities. The longer Lucentis is needed and used, the trend is less optimistic, and patients acknowledge a quality of life decrease. Total VFQ-25 score has well-defined rises and descents, favoring treatment efficacy as well as the necessity of additional injections according to clinical need.

Igor Anatolevich Loskutov

Semashko Clinic

Email: Loskoutigor@mail.ru
MD PhD Chief of the Eye Microsurgery department

  1. Klein R., Klein B. E., Linton K. L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study // Ophthalmology 1992. - Vol. 99. - N 6. - P. 933-943.
  2. Kahn H. A., Leibowitz H. M., Ganley J. P. et al. The Framingham Eye Study. I. Outline and major prevalence findings // Am. J. Epidemiol. - 1977. - Vol. 106, N 1. - P. 17-32.
  3. Sommer A., Tielsch J. M., Katz J. et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore // N. Engl. J. Med. - 1991. - Vol. 325, Nov 14; 325 (20). - P. 1412-1417.
  4. Klein B. E., Klein R. Cataracts and macular degeneration in older Americans // Arch. Ophthalmol. - 1982. - Vol. 100, Apr 100 (4). - P. 571-573.
  5. Friedman D. S., O’Colmain B. J., Munoz B. et al. Prevalence of age-related macular degeneration in the United States // Arch. Ophthalmol. - 2004. - Vol. 122, Apr 122 (4). - P. 564-572.
  6. Congdon N., O’Colmain B., Klaver C. C. et al. Causes and prevalence of visual impairment among adults in the United States // Arch. Ophthalmol. - 2004. - Vol. 122, Apr 122 (4). - P. 477-485.
  7. Friedman D. S., Katz J., Bressler N. M., et al. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey // Ophthalmology. - 1999. - Vol. 106, Jun 106 (6). - P. 1049-1055.
  8. Ferris F. L. III, Fine S. L., Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy // Arch. Ophthalmol. - 1984. - Vol. 102, Nov 102 (11). - P. 1640-1642.
  9. Ferrara and Davis-Smyth. The biology of vascular endothelial growth factor // Endocr-Rev. - 1997. - Vol. 18, Feb 18 (1). - P. 4-25.
  10. Rosenfeld, Brown, Heier et al. Ranibizumab for Neovascular Age-Related Macular Degeneration // N. Engl. J. Med. - 2006. - Vol. 355, Oct 5, 355 (14). - P. 1419-1431.
  11. Brown, Kaiser, Michels et al. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration // N. Engl. J. Med. - 2006. - Vol. 355, N 14. - P. 1432-1444.
  12. Brown G. C., Murphy R. P. Visual symptoms associated with choroidal neovascularization. Photopsias and the Charles Bonnet syndrome // Arch. Ophthalmol. - 1992. - Vol. 110, Sep 110 (9). - P. 1251-1256.
  13. West S. K., Rubin G. S., Broman A. T. et al. How does visual impairment affect performance on tasks of everyday life? The SEE Project. Salisbury Eye Evaluation // Arch. Ophthalmol. - 2002. - Vol. 120, Jun 120 (6). - P. 774-780.
  14. West C. G., Gildengorin G., Haegerstrom-Portnoy G. et al. Is vision function related to physical functional ability in older adults? // J. Am. Geriatr. Soc. - 2002. - Vol. 50, Jan 50 (1). - P. 136-145.
  15. Mangione C. M., Lee P. P., Pitts J., Gutierrez P., Berry S., Hays R. D. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-25VFQ) // Arch. Ophthalmol. - 1998. - Vol. 116, Nov 116 (11). - P. 1496-504.
  16. Mangione C. M., Lee P. P., Gutierrez P. R., Spritzer K., Berry S., Hays R. D. Development of the 25-item National Eye Institute Visual Function Questionnaire // Arch. Ophthalmol. - 2001. - Vol. 119, Jul 119 (7). - P. 1050-1058.
  17. Williams R. A, Brody B. L., Thomas R. G. et al: The psychosocial impact of macular degeneration // Arch. Ophthalmol. - 1998. - Vol. 116, Apr 116 (4). - P. 514-520.
  18. Slakter J. S., Stur M. Quality of Life in Patients With Age-related Macular Degeneration: Impact of the Condition and Benefits of Treatment // Surv. Ophthalmol. - 2005. - Vol. 50, May-Jun 50 (3). - P. 263-273.
  19. Brown D.M., Kaiser P.K., Michels M., Soubrane G. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration // N. Engl. J. Med. - 2006. - Vol. 355, Oct 5 355 (14). - P. 1432-1444.
  20. Rosenfeld P. J., Brown D. M., Heier J. S. et al. Ranibizumab for neovascular age-related macular degeneration // N. Engl. J. Med. - 2006. - Vol. 355, N 14. - P. 1419-1431.
  21. CATT Research Group, Martin D. F., Maguire M. G., Ying G. S., Grunwald J. E. () Ranibizumab and bevacizumab for neovascular age-related macular degeneration // N. Engl. J. Med. - 2011. - Vol. 364, N 20. - P. 1897-1908.
  22. Rostron E., McKibbin M. Visual impairment certification secondary to ARMD in Leeds, 2005-2010: is the incidence falling? // Eye. - 2012. - Vol. 26, N 7. - P. 933-936.
  23. Owen C. G., Jarrar Z., Wormald R., Cook D. G., Fletcher A. E. The estimated prevalence and incidence of late stage age related macular degeneration in the UK // Br. J. Ophthalmol. - 2012. - Vol. 96, N 5. - P. 752-756.
  24. Boyer D.S., Heier J.S., Brown D.M., Francom S.F., Ianchulev T. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration // Ophthalmology. - 2009. - Vol. 116, N 9. - P. 1731-1739.
  25. Regillo C.D., Brown D.M., Abraham P., Yue H., Ianchulev T., Schneider S., Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 // Am. J. Ophthalmol. - 2008. - Vol. 145, N 2. - P. 239-248.
  26. CATT Research Group, Martin D. F., Maguire M. G., Fine S. L., Ying G. S., Jaffe G. J., Grunwald J. E., Toth C., Redford M., Ferris F. L. Ranibizumab and bevacizumab for treatment of neovascular agerelated macular degeneration: 2-year results // Ophthalmology. - 2012. - Vol. 119, N 7. - P. 1388-1398.
  27. Klein R., Knudtson M. D., Cruickshaks K. J., Klein B. E. Further observation on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye Study // Arch. Ophthalmol. - 2008. - Vol. 126, N 1. - P. 115-121.
  28. Kelly S.P., Barua A. A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications // Eye. - 2011. - Vol. 25, N 6. - P. 710-716.
  29. Dagostar H., Ventura A.A., Chung J. Y., Shar A. S., Kaiser P. K. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration // Ophthalmology. - 2009. - Vol. 116, N 9. - P. 1740-1747.
  30. Gerding H., Loukopoulos V., Riese J., Herner L., Timmermann M. Results of flexible ranibizumab treatment in age-related macular degeneration and search of parameters with impact on outcome // Graefes Arch. Clin. Exp. Ophthalmol. - 2011. - Vol. 249, N 5. - P. 653-662.

Views

Abstract - 313

PDF (Russian) - 366

PlumX


Copyright (c) 2014 Loskutov I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.